Merck settles tax dispute with IRS for $2.3 billion

Share this article:
Merck has entered an agreement to settle its previously disclosed tax disputes with the Internal Revenue service for $2.3 billion. The settlement essentially brings to a close the IRS’s examination of the company for the period 1993-2001, the Whitehouse Station, NJ drugmaker said in a statement issued today. The figure of $2.3 billion will cover federal tax and net interest after deductions and penalties, Merck said. The IRS' examination of years subsequent to 2001 remains open. Merck announced in November that it faced potential tax liabilities totaling $5.58 billion from US and Canadian authorities related to disputes over accounting for past transactions.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...